Traumatic medical company Centre for Neuro Skills (CNS) revealed on Wednesday that COVID-19 has afflicted about 7m Americans and some may experience neurological complications from the virus, which may include stroke, encephalitis and respiratory distress.
COVID and its aftermath have created a new need for the work and CNS has been providing brain rehabilitation services for 40 years and has therapies to address memory loss, agitation and attention deficits associated with the infection, said CEO and founder Dr Mark Ashley.
This year, the company is celebrating its 40th anniversary with two new video series: "Patient Stories of Independence" demonstrating that rehabilitation is possible after acute care as well as recognizing longtime staff in "40 Years of Hope, Healing and Heart."
The Centers for Disease Control and Prevention (CDC) notes that more than 795,000 Americans suffer a stroke each year. The CDC reports that acute care and rehabilitation of brain injury patients in the United States costs USD9bn to USD10bn per year.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review